-
First participants dosed in new POINT-HD huntingtin-lowering trial
Latest News
-
A road less traveled: how making less huntingtin can alter somatic instability and may delay symptoms
CAG repeats can get longer over time as the HD gene is used, like the growing potholes and cracks in an old road. New research finds that blocking cells from using their HTT gene slows this wear and tear, which might slow the onset of symptoms in HD.
-
Not all in your head: digestive problems in HD
Huntington's disease mice absorb less nutrition from food – which might help explain why human patients lose weight.
-
Huntexil update: EMA asks for further trial
European Medicines Agency (EMA) tells NeuroSearch a European license for Huntexil in HD requires another large trial
-
KMO inhibitor drug improves lifespan of Huntington's disease mice
Positive results from tests of a new 'KMO inhibiting' drug in Huntington's disease mice
-
Meet the enemy: neutron ray reveals HD protein structure
Scientists use beams of neutrons to study the structure of clumps of mutant huntingtin protein
-
'Floating' gene-silencing drugs into the brain with exosomes
Exosomes – tiny bubbles made by cells – could be used to get gene silencing drugs from the bloodstream into the brain
-
Improving Huntington's disease clinical trial recruitment through patient and family education
How can we improve recruitment into Huntington's disease clinical trials? Talking directly with families works!
-
Chubby mice reveal the importance of the hypothalamus in Huntington's disease
Huntington's disease mice are fat but HD patients lose weight – is a brain area called the hypothalamus to blame?
-
The genetic 'gray area' of Huntington's disease: what does it all mean?
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-
Dimebon fails in late-stage human HD clinical trial
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
-
FDA: further trial needed for Huntexil approval in HD
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
